Who Controls the Rollout? Wall Street Distribution, ER AI Benchmarks, and Governance Under Pressure

Claire and Peter break down a day of AI stories where the real question is less about capability and more about deployment. They unpack reports of a major Anthropic joint venture designed to push generative AI across private-equity portfolios, and what that means for CIOs facing top-down standardisation and vendor lock-in risk. They also cover a Science study suggesting OpenAI’s o1 model can outperform emergency physicians on key triage and diagnosis tasks under uncertainty—raising urgent questions for hospitals around trials, liability, and clinical governance. Plus: Berkshire Hathaway’s disciplined “prove the value” stance, the UK Home Office’s funding for a Police.AI centre amid unsettled facial recognition oversight, market signals on AI capex and supply-chain constraints, emerging side-channel risks from encrypted traffic patterns, why filters and RLHF aren’t enough without architectural guardrails, neuromorphic chips moving toward low-power edge deployments, and how genAI is accelerating drug design faster than regulation can keep pace.About Six & FlowSix & Flow is a digital transformation consultancy helping businesses adapt, grow, and thrive in a fast-changing world. We specialise in AI, CRM, and revenue operations, blending strategy, technology, and creativity to deliver measurable impact. From scaling startups to global enterprises, we partner with ambitious teams to unlock growth through smart automation, customer-centric marketing, and forward-thinking sales enablement. Learn more at sixandflow.com. Hosted on Acast. See acast.com/privacy for more information.